Efficacy News and Research

RSS

New guideline recommends combined therapies for chronic insomnia treatment

A new clinical practice guideline from the American Academy of Sleep Medicine provides evidence‑based recommendations on the combined use of behavioral‑psychological and pharmacological therapies to treat chronic insomnia disorder in adults.

21 Apr 2026

Low-dose nivolumab injections shrink precancerous oral lesions

Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral lesions significantly reduced lesion size and risk of cancer progression, sparing most patients from surgery.

21 Apr 2026

Pinecone-inspired conduit enables suture-free repair of nerve injuries

As the authors detail, PNI is a prevalent neurological condition that often causes permanent sensory and motor dysfunction, severely impairing patient's quality of life.

21 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Injectable immunotherapy shrinks precancerous oral lesions in clinical trial

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

Molecular keyhole discovery offers new hope for personalized pain therapies

Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular 'keyhole', in the TRPM3 ion channel, a crucial sensor in pain signaling.

21 Apr 2026

Alzheimer’s monoclonal antibodies fail to deliver meaningful results

Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps in current therapeutic approaches.

21 Apr 2026

Phase I NSCLC trials shrink and cluster in major U.S. cities

Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest‑volume clinical trial sites largely located in major cities, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

Muscle energy recovery may explain fatigue in cancer survivors

Even apparently healthy cancer survivors often complain of extreme fatigue. They have finished treatment, the scans are clear, but they feel hollowed out, unable to walk to the mailbox or stay awake through dinner.

21 Apr 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

Targeting glutamine metabolism enhances CAR-macrophage cancer therapy

Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function.

20 Apr 2026

CBD shows promise, but this review warns the hype is outpacing the science

A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.

20 Apr 2026

Your new therapist: Chatty, leaky, and hardly human

Vince Lahey of Carefree, Arizona, embraces chatbots. From Big Tech products to "shady" ones, they offer "someone that I could share more secrets with than my therapist."

17 Apr 2026

Donor-derived dendritic cells teach the immune system to accept new livers

UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.

17 Apr 2026

Concerns rise over breast cancer risk and gender-based efficacy of Ocrevus

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - a form of MS thought to affect around 15 % of patients.

17 Apr 2026

Scientists link poor sleep to decreased chemotherapy response via the gut

Sleep deprivation has long been known to weaken the immune system. Now UF Health Cancer Institute researchers have made a startling discovery: The gut microbiota drives changes to the immune system caused by chronic sleep loss. These changes promote cancer progression, disrupt circadian rhythm and weaken the effectiveness of chemotherapy.

17 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

Researchers prove magnetic seizures are comparable to ECT in clinical response

A landmark international clinical trial led by researchers at the Centre for Addiction and Mental Health (CAMH) and University of California San Diego School of Medicine, published in The Lancet Psychiatry, has found that magnetic seizure therapy (MST) is as effective as electroconvulsive therapy (ECT)-the current gold-standard treatment for severe, treatment-resistant depression-with significantly fewer cognitive side effects. The study is the first large-scale, randomized clinical trial to directly compare MST with ECT, marking an important step toward a new treatment option for patients.

16 Apr 2026

Sunlight exposure via windows risks infant dehydration and skin damage

Researchers from the Universitat Politècnica de València, the Francesc de Borja University Hospital in Gandia and the La Ribera University Hospital, through the Fisabio Foundation, have found that sunlight passing through windows in homes is neither a safe nor a recommended alternative for preventing or treating neonatal jaundice, a condition affecting more than half of all newborns.

16 Apr 2026